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OBJECTIVE—Ectopic lipid storage in muscle (intramyocellular lipids [IMCL]) and liver
(hepatocellular lipids [HCL]) coexists with impaired myocellular ﬂux through ATP synthase
(fATPase) in certain cohorts with increased risk of type 2 diabetes. Because women with a
historyofgestationaldiabetesmellitus(pGDM)haveelevatedectopiclipidsanddiabetesrisk,
we tested whether deteriorated energy metabolism contributes to these abnormalities.
RESEARCHDESIGNANDMETHODS—Atotalof23glucose-tolerantnonobesepGDM
and eight women with normal glucose metabolism during pregnancy with similar age, body
mass, and physical activity underwent oral glucose tolerance tests (OGTT) and intravenous
glucose tolerance tests at 4–5 years after delivery. OGTT values ,463 mL z min
21 z m
22 were
considered to indicate insulin resistance. pGDM were further stratiﬁed into insulin-resistant
(pGDM-IR) and insulin-sensitive (pGDM-IS) groups. IMCL, HCL, and fATPase were measured
with
1H/
31P magnetic resonance spectroscopy.
RESULTS—pGDMhad36% higher fatmassand 12% lower insulin sensitivity.Log-transformed
fATPase was lower in pGDM (10.6 6 3.8 mmol z mL muscle
21 z min
21 vs. 12.1 6 1.4
mmol z mL muscle
21 z min
21, P , 0.03) and related to plasma adiponectin after adjustment for
bodyfat(r=0.44,P,0.04).IMCLwere61%and69%higherinpGDM-IR(P,0.05vs.pGDM-
IS)andinsulinresistantwomen(P,0.003vs.insulinsensitive),respectively.HCLweredoubled
(P , 0.05) in pGDM and insulin resistant women, and correlated positively with body fat mass
(r =0 . 5 0 ,P , 0.01) and inversely with insulin sensitivity (r = 20.46, P , 0.05).
CONCLUSIONS—Glucose-tolerant pGDM show increased liver fat but only slightly lower
muscular insulin sensitivity and ATP synthesis. This suggests that alteration of hepatic lipid
storage represents an early and predominant abnormality in this cohort.
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I
nsulin resistance tightly relates to
abdominal obesity and ectopic fat de-
position in skeletal muscle (intra-
myocellular lipids [IMCL]) and liver
(hepatocellular lipids [HCL]) (1). Obesity-
associated exposure of both tissues to
elevated free fatty acids (FFAs) (1) or
impaired secretion of the adipocytokine
adiponectin,which regulateslipidmetab-
olism and insulin action (2), contributes
to insulin resistance. Impaired myocellu-
lar mitochondrial ﬁtness (1) hasalso been
linked to insulin resistance.
In skeletal muscle, elevation of IMCL is
associated with diminished maximal oxida-
tive capacity (3). Insulin-resistant humans
with type 2 diabetes and their ﬁrst-degree
relatives can present with impaired ﬂux
through myocellular ATP synthase
(fATPase), the ﬁnal step of mitochon-
drial oxidative phosphorylation (4–6).
Women with a history of gestational
diabetes mellitus (pGDM) are also fre-
quently insulin resistant and more obese
than women after normoglycemic preg-
nancy. Their markedlyhigher diabetes risk
renders them as a suitable model of early
metabolic alterations preceding type 2
diabetes (7). The strongest predictors for
an early onset of diabetes include insulin
requirement and early diagnosis of GDM
during pregnancy and maternal BMI (7).
Increased IMCL identiﬁes women
who are more insulin resistant,diagnosed
earlier,andpronetorequireinsulinrather
thandietonlyduringpregnancy(8).Like-
wise, elevated HCL correlate tightly with
insulin resistance in pGDM (9) who also
exhibit lower plasma adiponectin, an-
other predictor of glycemic deterioration
(10).However,theroleofmyocellularen-
ergy metabolism for insulin resistance
and accumulation of IMCL and HCL in
this cohort is unknown.
We tested the primary hypothesis
that pGDM exhibit lower myocellular
fATPase than women with normal glu-
cose tolerance during pregnancy. We
furtherhypothesizedthatfATPasecorrelates
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Pathophysiology/Complications
ORIGINAL ARTICLEinversely with IMCL and insulin resistance
andthatinsulinresistantpGDMhavehigher
HCL and/or lower plasma adiponectin.
RESEARCH DESIGN AND
METHODS
Volunteers
Twenty-three pGDM and eight women
without any risk factors for type 2 di-
abetes serving as controls (CON) were
recruited from the outpatient service of
the Division of Endocrinology and Me-
tabolism, Department of Internal Medi-
cine III, Medical University of Vienna.
GDM was diagnosed according to the
criteria of the Fourth Workshop Confer-
ence of Gestational Diabetes. The women
had no disease and were not taking
medications. During their pregnancies,
the women were continuously seen in
the outpatient service so that all data on
diagnosis and treatment were recorded
andvalidated.FifteenpGDMhadbeenon
insulintherapy(IT),andeightpGDMhad
been on diet treatment (DT) only. They
wereinstructedtoingestanisocaloricdiet
(carbohydrate/protein/fat: 60/20/20%)
and refrain from any physical exercise
during the 3 days preceding the exami-
nations. Metabolic tests were performed
on different days during the ﬁrst phase
(days 5–8) of the menstrual cycle after
10–12-h overnight fasting. All partici-
pants gave written informed consent to
the protocol, which had been approved
by the institutional ethics board of the
Medical University of Vienna.
Oral glucose tolerance test
A solution containing 75 g of glucose was
ingested within 2 min, and venous blood
samples were collected for measurements
of glucose and hormones. During fasting,
insulin sensitivity was assessed with the
quantitative insulin-sensitivity check in-
dex (QUICKI) = 1/[log(fasting-glucose) +
log(fasting-insulin)],whichmostlyindicates
hepatic insulin sensitivity (11). Under dy-
namic conditions, the oral glucose insulin
sensitivity (OGIS) index (12) was used,
which quantiﬁes glucose clearance per
unit change of insulin and has been vali-
dated against the glucose clamp (12,13)
and in terms of reproducibility and vari-
ability (14). The OGIS correlates more
closely with total glucose disposal than
with hepatic insulin sensitivity in a study
directlycomparingtheglucoseclampwith
the oral glucose tolerance test (OGTT)
(11). Thus, we used OGIS as a measure
of whole-body insulin sensitivity during
glucose ingestion. Insulin delivered into
peripheral circulation was assessed with
the total area under the insulin concentra-
tion curve (AUCINS), calculated with the
trapezoidal rule. An integrated index of
b-cell function (adaptation index), as its
ability to compensate insulin resistance
by increasing insulin release, was calcu-
latedasOGIS3DAUCCP,whereDAUCCP
is the suprabasal area under the C-peptide
concentration curve. In addition, the fre-
quent sampling intravenous glucose toler-
ance test was performed and analyzed for
assessing SI as a measure of insulin sensi-
tivity and disposition index, DI = SI 3
DAIRGLUC as a measure of combined effects
of insulin secretion and sensitivity on glu-
cose disposal as described previously (15).
In vivo magnetic resonance
spectroscopy
Measurements were performed in partic-
ipants lying supine inside a 3-T whole-
body spectrometer (Bruker Biospin,
Ettlingen, Germany). 1)
31PM R S( m a g n e t i c
resonance spectroscopy): A 10-cm circular
double-resonant surface coil was posi-
tioned over the medial head of the right
gastrocnemius muscle. Intramyocellular
concentrations of inorganic phosphate
and ATP, as well as rate constant (kATP)
andunidirectionalfATPase,using thesatu-
ration transfer experiment, were measured
as described (4,16). 2)
1H MRS: A 10-cm,
circular, double-resonant surface coil was
applied above the right soleus muscle to
measure IMCL from localized
1Hs p e c t r a
usingtheseriesstimulatedechoacquisition
mode sequence within a volumeofinterest
of1.73cm
3(5).HCLwerequantiﬁedusing
the stimulated echo acquisition mode
within a volume of interest of 27 cm
3 (5).
Body fat mass and resting energy
expenditure
Body fat mass (BFM) was assessed from
bioimpedance analysis (Akern-RJL Sys-
tems,Florence,Italy).Predictionerrorsof
body composition equations estimating
percent fat free mass are based on em-
pirically derived measurement errors
associated with the reference method, hy-
drodensitometry. Resting energy expendi-
ture (REE) was assessed from indirect
calorimetry as described previously (8).
Laboratory tests
Plasma glucose was measured by the
hexokinase method (Hitachi Ltd., Tokyo,
Japan), HbA1c (A1C) was measured by
high-performance liquid chromatography
(VARIANT Hemoglobin Testing System,
Hercules, CA), and ultrasensitive C-reactive
protein was measured by particle-enhanced
immunonephelometry (N High-Sensitivity-
CRP Reagent, BN Systems; Dade Behring,
Deerﬁeld, IL). HDL- and LDL-cholesterol
were quantiﬁed using standard laboratory
procedures. Fasting plasma adiponectin
was measured in duplicate using an
enzyme-linked immunosorbent assay
system (Otsuka Pharmaceutical Co. Ltd.,
Tokyo, Japan) with human recombinant
adiponectin as a standard.
Calculations and statistics
Data were compared between pGDM and
CON.RelationshipsamongfATPase,IMCL,
HCL, insulin sensitivity, and metabolic and
inﬂammatory parameters were further ana-
lyzed in pGDM and CON, insulin-sensitive
(IS) subjects (n = 15), insulin-resistant (IR)
subjects (n = 16), insulin-sensitive (pGDM-
IS, n = 9), and insulin-resistant pGDM
(pGDM-IR, n =1 4 ) .T h ec u t o f fv a l u e
(462.8 mL z min
21 z m
22) for insulin re-
sistance was derived from OGIS values in
control women of this study and other
studies. The lowest quantile of the distri-
bution gave the value deﬁned as cutoff
point between normal and impaired
(lower) OGIS. The identical approach
has been applied in previous studies
(8,10). Further, all women and pGDM
were divided into three groups according
to OGIS tertiles.
Statistical analyses were performed
using SAS Software 9.1.3 (SAS Institute,
Inc., Cary, NC). Data are presented as
means 6 SD intextand tables orbox-and-
whisker plots in ﬁgures. Data exhibiting
skewed distribution were log-transformed
before statistical analysis. Comparisons
between groups were performed using
ANOVAformetricparameters.TheTukey
test was applied for post hoc testing, and
the Wilcoxon rank-sum test was applied
for nonparametric parameters. Pearson
correlation coefﬁcients were computed
for normally distributed data. Spearman
correlation coefﬁcients were computed
in case of non-normal distribution. Bivar-
iate correlation analyses were performed
by applying partial correlations adjusting
for BFM. P , 0.05 was considered statis-
tically signiﬁcant.
RESULTS
Study population
All women had normal glucose tolerance
b a s e do nt h e7 5 - gO G T Ta n dc o m p a r a b l e
habitual physical activities according to
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Prikoszovich and AssociatesBaecke’s questionnaire (Table 1). pGDM
had greater BFM and waist circumference
than CON (Table 1). This also held true
forpGDM-IR,butnotforpGDM-IS.Adjust-
ment for BFM abolished the difference of
HDL-cholesterolbetweenpGDMandCON.
Insulin sensitivity and secretion
pGDM had marginally higher postload
glycemia (Table 2) and lower OGIS than
CON(Fig.1B).WithinpGDM,OGISwas
21% lower (P , 0.007) in the insulin re-
sistant than in the insulin sensitive sub-
group. After adjustment for BFM, the
difference in OGIS between pGDM-IR
and pGDM-IS remained (adjusted means:
408 mL z min
21 z m
22 vs. 513 mL z
min
21 z m
22; P , 0.0001) and tended to
be lower even in pGDM-IS compared with
CON (adjusted means: 412 mL z min
21 z
m
22 vs. 514 mL z min
21 z m
22; P = 0.06).
The intergroup difference for postload
glycemia disappeared. Insulin delivery
(AUCINS) was higher in pGDM-IR com-
p a r e dw i t hp G D M - I S( T a b l e2 ) .T h e
adaptation index was not different be-
tween pGDM and CON, reﬂecting nor-
mal glucose tolerance due to adequate
b-cell compensation for a minor degree
of insulin resistance in pGDM (data
not shown). Fasting C-peptide reﬂect-
ing basal insulin secretion rates and
AUCGLUC were higher in pGDM-IR than
in pGDM-IS (P , 0.05 and P = 0.0007;
Table 2), although these differences dis-
appeared after adjustment for BFM.
Myocellular energy metabolism
pGDMhad12%lowerfATPasethanCON
(Fig. 1A) only on log-transformation of
the data (P , 0.03), which had to be per-
formed because of outliers. Adjusting for
BFMdiminishedthedifference(P=0.37).
Interestingly, fATPase did not differ be-
t w e e nt h eI Ra n dI Ss u b g r o u p so f
pGDM and the total population (P =
0 . 3 0 ;F i g .1 C). Further, fATPase did not
differ between lowest and highest OGIS
tertiles, both in all women (P . 0.2) and
in pGDM alone (P . 0.4). kATP was not
different between pGDM and CON
(0.06 6 0.02 1/s vs. 0.07 6 0.01 1/s; P =
0.1) or between subgroups (pGDM-IR vs.
pGDM-IS:0.0660.021/svs.0.0660.02
1/s; P = 0.6). fATPase was also comparable
Table 1—Clinical characteristics and metabolic parameters (means 6 SD) of women with pGDM and their insulin-resistant (pGDM-IR) and
insulin-sensitive (pGDM-IS) subgroups compared with control subjects (CON)
pGDM pGDM-IR pGDM-IS CON P
N 23 14 9 8
Age (years) 37 6 53 7 6 5.9 39 6 33 5 6 4N S * N S † NS‡ 0.06§
Time after delivery (m) 57 6 11 56 6 14 59 6 64 5 6 15 0.02* NS† NS‡ NS§
BMI (kg/m
2) 25.5 6 3.6 26.5 6 3.0 24.2 6 4.1 25.0 6 2.9 NS* NS† NS‡ NS§
BFM (kg) 24.5 6 6 26.1 6 5.1 22.2 6 6.8 18.0 6 3.3 ,0.03* NS† ,0.02‡ NS§
Waist circumference (cm) 85.5 6 9.4 87.9 6 7.3 82.2 6 11.2 76.0 6 8.2 0.03* NS† 0.02‡ NS§
Triglycerides (mg/dL) 85.2 6 38.6 94.1 6 42.4 71.3 6 28.7 97.0 6 37.5 NS* NS† NS‡ NS§
HDL-cholesterol (mg/dL) 55.6 6 12.5 52.8 6 13.3 59.9 6 10.4 64.5 6 10.1 ,0.05* NS† 0.02‡ NS§
A1C (%) 5.4 6 0.4 5.3 6 0.5 5.4 6 0.3 5.2 6 0.2 NS* NS† NS‡ NS§
GGT (units/L) 18 6 72 0 6 71 5 6 62 3 6 24 NS* 0.03† NS‡ NS§
Adiponectin (mg/mL) 7.9 6 2.5 7.3 6 2.2 8.9 6 2.7 9.1 6 2.3 NS* NS† NS‡ NS§
us-CRP (mg/dL) 0.19 6 1.67 0.20 6 0.17 0.17 6 0.18 0.25 6 0.24 NS* NS† NS‡ NS§
Physical activity score 2.68 6 0.51 2.58 6 0.5 2.85 6 0.53 2.75 6 0.12 NS* NS† NS‡ NS§
Resting energy expenditure (kcal/24 h) 1541 6 255 1587 6 250 1449 6 270 1440 6 215 NS* NS† NS‡ NS§
IR was deﬁned by means of OGIS ,462.8 mL z min
21 z m
22. GGT, gamma glutamyl transferase; us-CRP, ultra-sensitive C-reactive protein. *pGDM vs. CON.
†pGDM-IS vs. pGDM-IR. ‡pGDM-IR vs. CON. §pGDM-IS vs. CON.
Table 2—Glucose metabolism, insulin sensitivity, and secretion (all expressed as means 6 SD) in women with pGDM and their
insulin-resistant (pGDM-IR) and insulin-sensitive (pGDM-IS) subgroups compared with control subjects (CON)
pGDM pGDM-IR pGDM-IS CON P
N 23 14 9 8
Fasting glucose (mg/dL) 90 6 9 92.3 6 11 86.3 6 38 4 6 9N S * N S † NS‡ NS§
Fasting insulin (mU/mL) 9.8 6 5.7 11.6 6 6.5 7.2 6 2.5 7.6 6 1.6 NS* NS†
Fasting C-peptide (ng/mL) 1.89 6 0.98 2.26 6 1.12 1.37 6 0.42 2.00 6 0.43 NS* ,0.05†
QUICKI 0.348 6 0.027 0.337 6 0.024 0.364 6 0.024 0.357 6 0.018 NS* ,0.05†
1-h glucose (mg/dL)OGTT 144 6 42 155 6 44 126 6 32 106 6 47 NS* NS† 0.04‡ NS§
2-h glucose (mg/dL)OGTT 109 6 32 117 6 39 98 6 12 85 6 22 0.05* NS† NS‡ NS§
Fasting FFA (mmol/L)OGTT 551 6 206 522 6 150 597 6 277 659 6 256 NS* NS†
2-h FFA (mmol/L)OGTT 33 6 18 39 6 19 23 6 12 42 6 25 NS* ,0.04† NS‡ NS§
AUCGLUC (mol/L min) 1.21 6 0.13 1.30 6 0.08 1.10 6 0.07 1.07 6 0.16 NS* ,0.05†
AUCINS (nmol/L min) 61.75 6 41.0 74.76 6 47.8 41.52 6 12.4 50.39 6 41.6 NS* ,0.05†
IR was deﬁned by means of OGIS ,462.8 mL z min
21 z m
22. Fasting FFA, basal free fatty acid; 2-h FFA, free fatty acid at 120 min; QUICKI, quantitative insulin-
sensitivitycheckindex;AUCGLUC,areaunder theglucose concentrationcurve;AUCINS,areaundertheinsulinconcentrationcurve. *pGDMvs.CON.†pGDM-IRvs.
pGDM-IS. ‡pGDM-IR vs. CON. §pGDM-IS vs. CON.
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ATP synthesis in gestational diabetes mellitusbetween pGDM with and without insulin
therapy (IT) during their pregnancies.
Ectopic lipids
IMCL were not different between pGDM
and CON (Fig. 2A), but 61% higher in
pGDM-IR than in pGDM-IS (P , 0.05).
Among all women, IR women had 69%
higher IMCL than IS women (P , 0.007;
Fig. 2C). pGDM on IT during their preg-
nancies had higher IMCL than those on
diet treatment (DT) (IT vs. DT: 0.86 6
0.29% vs. 0.51 6 0.25%, P = 0.01).
pGDM had 2.5-fold higher HCL(P ,
0.05) than CON (Fig. 2B). Likewise, HCL
weretwiceashighinIRthaninISsubjects
(P , 0.05; Fig. 2D), but not different
among pGDM subgroups. Adjusting for
BFM diminished these differences. HCL
were not different between pGDM with
or without IT during pregnancy (DT vs.
IT:HCL4.865.0%signalvs.3.162.4%
signal).
Correlation analyses for fATPase
and HCL
Partial correlation analysis, controlled for
BFM, revealed a relationship between
fATPase and plasma adiponectin across
all women (P , 0.04, r = 0.44). fATPase
did not relate to measures of insulin sen-
sitivity (OGIS: r
2 = 0.002, SI: r
2 = 0.07) or
glucose tolerance (AUCGLUC: r
2 = 0.005)
in any subgroup. However, the disposi-
tion index related to HCL (r = 0.59, P =
0.002)and fATPase(r =0.37,P = 0.04) in
all women. Fasting plasma FFA did not
relate to fATPase, whereas 2-h postload
plasma FFA related to HCL (r = 0.59,
P = 0.01) and insulin sensitivity as as-
sessed from OGIS (r = 20.44, P = 0.04)
or SI (r = 20.42, P = 0.04) in pGDM.
HCL related to insulin sensitivity (r =
20.47,P,0.02)acrossallwomenandto
IMCL (r = 20.59, P = 0.05) and A1C
across IR (r = 0.64, P , 0.03). After ad-
justment for BFM, HCL still related to
A1C (r = 0.57, P , 0.02) in all women.
Within pGDM, the correlation of HCL
with hip circumference (r = 0.59, P =
0.04) and A1C (r = 0.62, P = 0.03) re-
mained after adjustment for BFM.
CONCLUSIONS—Wefoundthatmyo-
cellular fATPase is lower in pGDM than in
CON and does not relate to insulin sensi-
tivity or IMCL, but correlates positively
withplasmaadiponectinacrossallwomen,
suggesting a yet unknown relationship
between energy metabolism and adipocyte
function. HCL were greater in pGDM, and
HCL and postload FFA were negatively
related to insulin sensitivity.
Our pGDM featured slightly greater
fat mass, postload glycemia, and insulin
resistance than CON. Except for HDL-
cholesterol, they did not differ from CON
in other variables, including physical
activity and resting energy expenditure.
This held true even for pGDM-IR, sug-
gesting that this cohort is at lower risk for
type 2 diabetes than other mostly obese
and glucose-intolerant pGDM, but al-
ready exhibits distinct metabolic features.
We found moderately lower myocel-
lular fATPase in pGDM compared with
CON, which was signiﬁcant only on log-
transformation. Our cohort was carefully
matched to CON, except for insulin
sensitivity, and probably bears a low risk
Figure 1—MyocellularfATPase(AandC)and insulinsensitivity(BandD)asassessedfromthe
OGTT (OGIS) in pGDM compared with CON (A and B) and in IR and IS subgroups of the total
cohort according to their insulin sensitivity (OGIS) (C and D). Data are presented as box-and-
whiskerplots.Boxesdelineatelowerandupperquartile,whiskersrepresentminimaandmaxima,
medians are indicated by solid line within boxes, and small circles/asterisks represent experi-
mental outliers. fATPase: pGDM vs. CON (10.6 6 3.8 mmol z mL muscle
21 z min
21 vs. 12.1 6
1.4mmolzmLmuscle
21 zmin
21; P,0.12,**afterlogtransformation:P,0.03),OGIS(glucose
clearance): pGDM vs. CON (447 6 67 mL z min
21 z m
22 vs. 508 6 87 mL z min
21 z m
22; P ,
0.05), fATPase: IR vs. IS (10.7 6 3.7 mmol z mL muscle
21 z min
21 vs. 11.4 6 3.0 mmol z mL
muscle
21zmin
21;P=0.6NS),OGIS(glucoseclearance):IRvs.IS(402638mLzmin
21zm
22vs.
528 6 46 mL z min
21 z m
22; P , 0.0001).
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Prikoszovich and Associatesfor rapid progression to diabetes. The
observed small differences could also be
due to this speciﬁc cohort maintaining
normal glucose toleranceforupto4 years
postpartum. The difference in fATPase
between pGDM and CON, however, van-
ished on correction for BFM and was not
found when comparing pGDM-IR with
pGDM-IS. Although one might speculate
that the reduction of fATPase resulted
from greater body fat content as reported
forobeseinsulin-resistantandoverweight
type 2 diabetes cohorts (17), our data
do not allow such a conclusion. Basal
fATPase, the ﬁnal step of mitochondrial
oxidative phosphorylation, is impaired
only in some cohorts presenting with se-
vere insulin resistance and elevated IMCL,
such as elderly and lean relatives of pa-
tients with type 2 diabetes (4). The overall
higher insulin sensitivity compared with
o t h e rp o p u l a t i o n sa tr i s kf o ro rh a v i n g
overt type 2 diabetes (5,6,18) suggests
that muscle metabolism was almost nor-
mal in our pGDM.
The ﬁnding that IMCL were not
different between pGDM and CON, but
;69%higherinIRthanIS,underlinesthe
contention that IMCL generally correlate
with insulin resistance (8,19) and can be
elevated in patients with type 2 diabetes
andtheirinsulin-resistant ﬁrst-degree rel-
atives (4). Further, the pGDM of our pre-
vious study exhibited higher IMCL along
with greater insulin resistance and BFM
(8). Of note, baseline fATPase is not nec-
essarily different in patients with overt
type 2 diabetes (5,6), indicating that mi-
tochondrial dysfunction is not a uniform
featureoftype2diabetes(5).Theincrease
in IMCL relates to not only diminished
mitochondrial capacity for oxidative
phosphorylationbutalsolipidavailability.
Plasma FFA elevation decreases insulin-
stimulated fATPase and insulin sensitiv-
ity before changes in IMCL (16). Of note,
postchallenge plasma FFAs were not dif-
ferent between pGDM and CON and only
slightly higher in IR-pGDM than in IS-
pGDM. The increase in insulin secretion
further argues against mitochondrial dys-
function at the level of the b-cell, which
h a sb e e no b s e r v e di nG D Ma n ds o m e
pGDM (20).
Despite the only discrete alterations
inmuscularmetabolism,liverfatcontent
w a sm o r et h a nd o u b l ei na l lp G D Ma n d
even three times more in IR-pGDM
compared with that in CON, which was
still below the detection limits of clinical
routine ultrasound. Higher HCL have
been reported in obese pGDM (9) and
type 2 diabetic patients, in whom HCL
tightly correlate with whole-body and
hepatic insulin resistance (5). Steatosis
even predicts the development of insulin
resistance, type 2 diabetes, and car-
diovascular end points (1,21). Of note,
similar to skeletal muscle, impaired mi-
tochondrial function has been recently
detected in livers of patients with type 2
diabetes (1,22). It has been proposed
that primary muscular insulin resistance
promotes shifting of ingested carbo-
hydrates away from skeletal muscle to
hepatic de novo lipogenesis, thereby in-
creasing HCL independently of obesity
( 1 8 ) .A l t e r n a t i v e l y ,s teatosis and/or im-
paired hepatic mitochondrial function
could lead to muscular insulin resistance
(1,22). We cannot address this issue di-
rectly, because liver biopsies are not
Figure 2—IMCL and HCL. Ectopic lipids in skeletal muscle (IMCL; A and C) and liver (HCL; B
and D) of pGDM compared with CON (A and B) and in IR and IS subgroups of the total cohort
accordingtotheirinsulinsensitivity(OGIS)(CandD).Datapresentedasbox-and-whiskerplots.
Boxes delineate lower and upper quartile, whiskers represent minima and maxima, respectively,
medians are indicated by solid line within boxes, and small circles/asterisks represent experi-
mental outliers. IMCL: pGDM vs. CON (0.73 6 0.32% H2O vs. 0.69 6 0.5% H2O; P =0 . 0 8N S )
HCL:pGDMvs.CON(3.763.5%vs.1.560.9%signal;P,0.05)IMCL:IRvs.IS(0.9060.3%
H2O vs. 0.54 6 0.32% H2O; P , 0.003) HCL: IR vs. IS (4.0 6 3.3% vs. 2.0 6 1.8% signal; P ,
0.05).
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ATP synthesis in gestational diabetes mellituspermitted in healthy humans and nonin-
vasive assessment with in vivo
31PM R S
was not available.
In pGDM, the 2-h post-glucose load
plasma FFA further correlated positively
with HCL and negatively with whole-
body insulin sensitivity. Even after cor-
rection for BFM, pGDM and their IR
subgroup also exhibited positiverelation-
ships of HCL with hip circumference and
A1C. Of note, despite the greater BFM,
none of the anthropometric parameters
reached the cutoff values of the metabolic
syndrome. From this it seems that im-
paired insulin action in these pGDM is
primarilylocatedattheleveloftheliverand
already present in the glucose-tolerant
state.
Steatosis may result not only from
abnormal fat metabolism but also from
disturbed cytokine release. Of note,
pGDM exhibit higher HCL and lower
plasma adiponectin, which is a sensitive
predictor for future deterioration of glu-
cose metabolism (10). Adiponectin has
been linked to improved muscular and
hepatic insulin sensitivity, which might
result from anti-inﬂammatory and anti-
atherogenic activity, decreased triglyceride
synthesis, and stimulated b-oxidation (2).
Adiponectin may also increase muscular
mitochondrial number and function, and
exert antidiabetic effects (23). In support
of this contention, the current study
showed that plasma adiponectin relates
positively to fATPase in all women after
adjustment for BFM. Moreover, preven-
tion of the development of type 2 diabetes
in pGDM by thiazolidinediones (24,25)
could be mediated by increased plasma
adiponectin with subsequent reduction
of HCL and hepatic and peripheral insu-
lin resistance. In addition, primary ab-
normal hepatic mitochondrial function
could lead to steatosis, because patients
with type 2 diabetes have reduced hepa-
tocellular ATP levels that correlate with
hepatic insulin sensitivity and HCL (22).
The limitations of the study are the
small sample size and the speciﬁc selec-
tion of pGDM, which restrict the extrap-
olation of the results to all pGDM. On the
otherhand,theselectedgroupunderwent
intensive phenotyping, including tissue-
speciﬁc metabolic assessment.
In summary, glucose-tolerant non-
obesepGDMdonotshowmajoralterations
ofmuscleglucoseandenergymetabolism,
but already exhibit a subclinical increase
of liver fat content suggesting early ab-
normalities or adaptations of hepatic
metabolism.
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